0.3143
4.12%
-0.0111
Fibrogen Inc stock is traded at $0.3143, with a volume of 748.91K.
It is down -4.12% in the last 24 hours and down -14.92% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
See More
Previous Close:
$0.3254
Open:
$0.3254
24h Volume:
748.91K
Relative Volume:
0.62
Market Cap:
$31.91M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-0.0927
EPS:
-3.39
Net Cash Flow:
$-317.54M
1W Performance:
+1.89%
1M Performance:
-14.92%
6M Performance:
-72.63%
1Y Performance:
-51.81%
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
409 ILLINOIS STREET, SAN FRANCISCO, CA
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
Jul-16-21 | Downgrade | Stifel | Buy → Hold |
Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
Feb-01-21 | Initiated | H.C. Wainwright | Buy |
Oct-26-20 | Initiated | Raymond James | Underperform |
Jul-10-20 | Resumed | Stifel | Buy |
May-01-20 | Initiated | Cowen | Market Perform |
Apr-27-20 | Initiated | BofA/Merrill | Neutral |
May-29-19 | Resumed | Goldman | Neutral |
May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
Apr-12-19 | Initiated | Piper Jaffray | Neutral |
Feb-11-19 | Resumed | Stifel | Buy |
Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
Aug-08-17 | Reiterated | Leerink Partners | Outperform |
Aug-08-17 | Reiterated | Stifel | Buy |
Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
Jul-11-17 | Initiated | Jefferies | Buy |
Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-21-16 | Initiated | Credit Suisse | Neutral |
Dec-04-15 | Initiated | Citigroup | Buy |
Sep-23-15 | Initiated | Lake Street | Hold |
Jul-29-15 | Initiated | Citigroup | Buy |
Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewswire
Metrics That Matter About FibroGen Inc (NASDAQ: FGEN) - Stocks Register
FGEN stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding - Simply Wall St
FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
FGEN stock touches 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com - Defense World
The growth track for FibroGen Inc (FGEN) has changed recently - SETE News
Should investors be concerned about FibroGen Inc (FGEN)? - US Post News
Cubist Systematic Strategies LLC Has $256,000 Stock Holdings in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Market Watch: FibroGen Inc (FGEN)’s Noteworthy Gain, Closing at 0.36 - The Dwinnex
Pulmonary Fibrosis Drug Market Size & Analysis By 2024 -2034 -Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., – IndiaPolitics.com - IndiaPolitics.com
Sei Investments Co. Purchases 41,442 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Financial Review: FibroGen (NASDAQ:FGEN) and Oncotelic Therapeutics (OTCMKTS:OTLC) - Defense World
FibroGen's US$6.2m Market Cap Fall Books Insider Losses - Simply Wall St
FibroGen Inc [FGEN] Chief Medical Officer makes an insider acquire of 22,123 shares worth 25,884. - Knox Daily
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts - Yahoo Finance
Investors in cash trouble should check out FibroGen Inc (FGEN) - SETE News
FGEN stock touches 52-week low at $0.33 amid market challenges By Investing.com - Investing.com South Africa
FGEN stock touches 52-week low at $0.33 amid market challenges - Investing.com Australia
A year in review: FibroGen Inc (FGEN)’s performance in the last year - US Post News
Trading Day Triumph: FibroGen Inc (FGEN) Ends at 0.37, a -8.07 Surge/Plunge - The Dwinnex
FibroGen Inc Inc. (FGEN) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Investing in FibroGen Inc (FGEN): What You Must Know - Knox Daily
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World
FibroGen will pay $10M to exit HQ lease in SF’s Mission Bay - The Real Deal
FibroGen Suit Alleging Disclosure Failures Tossed In Del. - Law360
FibroGen to exit Mission Bay lease earlySan Francisco Business Times - The Business Journals
FibroGen Cuts Costs by Terminating San Francisco Lease Early - TipRanks
FibroGen Board Beats Lawsuit Over Failed AstraZeneca Partnership - Bloomberg Law
Point72 DIFC Ltd Acquires 45,990 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Stocks of FibroGen Inc (FGEN) are poised to climb above their peers - SETE News
FibroGen Inc (FGEN) stock: A year of ups and downs - US Post News
Doheny Asset Management CA Buys New Shares in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Point72 DIFC Ltd Boosts Stake in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
475,716 Shares in FibroGen, Inc. (NASDAQ:FGEN) Purchased by XTX Topco Ltd - Defense World
FibroGen Inc [FGEN] Investment Appeal on the Rise - Knox Daily
Market Insights: FibroGen Inc (FGEN)’s Notable Drop of -1.78, Closing at 0.41 - The Dwinnex
Is FibroGen Inc (FGEN) a threat to investors? - US Post News
FibroGen faces potential Nasdaq delisting over share price - Investing.com India
FibroGen faces potential Nasdaq delisting over share price By Investing.com - Investing.com Australia
Investing in FibroGen Inc (FGEN) might be a great opportunity, but the stock is a bit overvalued - US Post News
FGEN (FibroGen Inc) may reap gains as insiders became active recently - Knox Daily
Acadian Asset Management LLC Acquires 860,854 Shares of FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen Announces Board Member Resignations and Committee Appointments - TipRanks
FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com - Defense World
FibroGen announces executive departures amid cost cuts By Investing.com - Investing.com Australia
FibroGen announces executive departures amid cost cuts - Investing.com
FibroGen CFO, CMO to leave company by year's end - MSN
FibroGen Executives Depart Amid U.S. Operations Overhaul - TipRanks
Fibrogen, Inc. Announces Termination of Juan Graham as Chief Financial Officer, Effective December 15, 2024 - Marketscreener.com
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Wettig Thane | CEO |
Mar 07 '24 |
Buy |
1.91 |
50,000 |
95,470 |
470,178 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):